Shares of Sequenom rose 32 percent for the five-day trading week ended Tuesday to lead all stocks in the BCW Index.
 
The gain follows last week’s increase of 23 percent for Sequenom. Last week, the company announced that it had licensed a next-generation sequencing technology from Harvard University.
 
Shares of Cepheid and Bio-Rad Laboratories also had strong weeks, rising 13.5 percent and 13.3 percent, respectively.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.